Format

Send to

Choose Destination
Thorac Surg Clin. 2014 Aug;24(3):333-49. doi: 10.1016/j.thorsurg.2014.04.005. Epub 2014 Jun 9.

Peptide receptor radionuclide therapy for advanced neuroendocrine tumors.

Author information

1
Division of Nuclear Medicine, European Institute of Oncology, via Ripamonti 435, Milan 20141, Italy. Electronic address: lisa.bodei@ieo.it.
2
Division of Health Physics, European Institute of Oncology, via Ripamonti 435, Milan 20141, Italy.
3
Department of Surgery, Yale School of Medicine, 310 Cedar Street, New Haven, CT 06520, USA.
4
Division of Nuclear Medicine, European Institute of Oncology, via Ripamonti 435, Milan 20141, Italy.
5
Radiometabolic Unit, Department of Nuclear Medicine, IRST-IRCCS, Via Maroncelli 40, Meldola 47014, Italy.
6
Department of Surgery, Yale School of Medicine, 310 Cedar Street, New Haven, CT 06520, USA; Clifton Life Sciences, Branford, CT 06405, USA.
7
Division of Nuclear Medicine, European Institute of Oncology, via Ripamonti 435, Milan 20141, Italy; Radiometabolic Unit, Department of Nuclear Medicine, IRST-IRCCS, Via Maroncelli 40, Meldola 47014, Italy.

Erratum in

  • Thorac Surg Clin. 2014 Nov;24(4):xv.

Abstract

Peptide receptor radionuclide therapy (PRRT) consists of the systemic administration of a synthetic peptide, labeled with a suitable β-emitting radionuclide, able to irradiate tumors and their metastases via internalization through a specific receptor (usually somatostatin S2), over-expressed on the cell membrane. After almost 2 decades of experience, PRRT, with either (90)Y-octreotide or (177)Lu-octreotate, has established itself to be an efficient and effective therapeutic modality. As a treatment, it is relatively safe up to the known thresholds of absorbed and bio-effective isotope dosages and the renal and hematological toxicity profiles are acceptable if adequate protective measures are undertaken.

KEYWORDS:

Bone marrow; Bronchopulmonary; Carcinoid; Gastroenteropancreatic neuroendocrine tumor; Hepatic neuroendocrine metastasis; PRRT; Peptide receptor radionuclide therapy; Renal toxicity

PMID:
25065935
DOI:
10.1016/j.thorsurg.2014.04.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center